Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551531 | 1.00 | PTPN11 (0.53) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL25263333 | 0.86 | PTPN11 (0.53) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL29890817 | 0.85 | GPR119 (0.56) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL27046549 | 0.85 | GPR119 (0.56) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL24120762 | 0.84 | GPR119 (0.53) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL29891363 | 0.83 | PTPN11 (0.50) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL21551735 | 0.83 | PTPN11 (0.50) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL24964179 | 0.82 | GPR119 (0.61) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL1447940 | 0.82 | GPR119 (0.65) | PTPN11GPR119MAPTACHECKS1B | |
| SCHEMBL31181001 | 0.81 | GPR119 (0.55) | PTPN11GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | PTPN11 4469/4885GPR119 2318/4885MAPT 3082/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | PTPN11 4469/4885GPR119 2318/4885MAPT 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.